Growth of biomarkers in lung cancer drug development
While there have been huge improvements in the treatment of cancer in the past decade, for some cancers the therapies still fall short in their efficacy.
Despite an estimated $307 billion due to be invested into cancer drug development globally by 2026 as pharmaceutical and biotech companies strive to develop the most effective treatments, certain cancers continue to have low survivability rates.
Meanwhile, for patients the side effects of life-prolonging treatments can be severe.
Taking lung cancer as an example, while the five-year survival rate for the condition has more than doubled since 2005, it remains a very difficult cancer to detect and treat, with only 10% of people surviving ten years following diagnosis.
Check out the rest of the feature here
Source link
#Marking #time #PharmaTimes
